A Phase 2 interventional study of Atacicept and Atacicept in Relapsing Multiple Sclerosis, sponsored by EMD Serono. Terminated at 51 sites in 17 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-05-24.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany — none open to participants now, 1 under way, none of them phase 3. Multiple Sclerosis · Merck KGaA, Darmstadt, Germany.
Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one is the 14th largest by enrollment of the 33 interventional ones that give a count, is one of 13 that started in 2008, is one of 9 in phase 2, and was the 8th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 664 are open to participants now.
Browse Multiple Sclerosis studies →None of the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, anywhere →
Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 13 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 219 across the 33 interventional studies, 253 across the 38 observational. Of the 70 that completed or were terminated, 42 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent magnetic resonance imaging (MRI). This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Atacicept
Drug: Atacicept
Drug: Atacicept
Drug: Placebo matched to atacicept
Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per Scan
Analysis of T1 Gd-enhancing lesions was done using magnetic resonance imaging (MRI) scans. Only post-baseline scans were included in the calculation of this endpoint (excluding the Study Day 1 scan which had been conducted before first dosing).
Time frame: Weeks 12 to 36
Number of New T1 Gd-enhancing Lesions Per Participant
Analysis of new T1 Gd-enhancing lesions was done using MRI scans.
Time frame: Weeks 12, 24, 36
Percentage of Participants Free From Relapses
A relapse was defined as the fulfillment of all the following criteria: a) neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both i) neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and ii) neurological abnormality lasting for at least 24 hours; b) absence of fever or known infection (fever with temperature \[axillary, orally, or intrauriculary\] greater than (\>) 37.5 degrees Celsius or 99.5 degrees Fahrenheit); and c) objective neurological impairment, correlating with the participant's reported symptoms, defined as either i) increase in at least 1 of the functional systems of the Expanded Disability Status Scale (EDSS), or ii) increase of the total EDSS score. Percentage of participants free from relapses during 36-week treatment period was reported.
Time frame: Baseline up to Week 36
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug up to 12 weeks after the last dose of the study drug that were absent before treatment or that worsened relative to pretreatment state. Number of subjects with TEAEs included subjects with both non serious and serious TEAEs.
Time frame: From the first dose of study drug administration up to 12 weeks after the last dose of the study drug
| Milestone | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Started | 63 | 63 | 64 | 65 |
| Treated | 63 | 63 | 63 | 65 |
| Completed | 23 | 21 | 21 | 25 |
| Not completed | 40 | 42 | 43 | 40 |
| Withdrew: Adverse event | 0 | 1 | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 3 | 3 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Premature termination of clinical trial | 37 | 32 | 35 | 35 |
| Withdrew: Randomized, but not treated | 0 | 0 | 1 | 0 |
| Withdrew: Other | 1 | 5 | 1 | 4 |
Analysis of T1 Gd-enhancing lesions was done using magnetic resonance imaging (MRI) scans. Only post-baseline scans were included in the calculation of this endpoint (excluding the Study Day 1 scan which had been conducted before first dosing).
| lesions/participant/scan | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Participant Per Scan | 3.07 (1.40 to 6.77) | 2.26 (0.97 to 5.27) | 2.30 (1.08 to 4.92) | 2.49 (1.18 to 5.27) |
Analysis of new T1 Gd-enhancing lesions was done using MRI scans.
| lesions/participant | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Week 12 (n=55, 45, 50, 55) | 2.55 ± 7.95 | 2.71 ± 7.67 | 3.20 ± 6.41 | 2.96 ± 6.58 |
| Week 24 (n=41, 34, 37, 41) | 0.83 ± 1.70 | 1.50 ± 2.79 | 1.54 ± 2.96 | 1.54 ± 2.94 |
| Week 36 (n=23, 22, 24, 26) | 0.43 ± 0.90 | 1.68 ± 5.09 | 1.38 ± 1.93 | 0.54 ± 1.07 |
A relapse was defined as the fulfillment of all the following criteria: a) neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both i) neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and ii) neurological abnormality lasting for at least 24 hours; b) absence of fever or known infection (fever with temperature \[axillary, orally, or intrauriculary\] greater than (\>) 37.5 degrees Celsius or 99.5 degrees Fahrenheit); and c) objective neurological impairment, correlating with the participant's reported symptoms, defined as either i) increase in at least 1 of the functional systems of the Expanded Disability Status Scale (EDSS), or ii) increase of the total EDSS score. Percentage of participants free from relapses during 36-week treatment period was reported.
| percentage of participants | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Percentage of Participants Free From Relapses | 81.0 | 69.8 | 71.9 | 61.5 |
An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug up to 12 weeks after the last dose of the study drug that were absent before treatment or that worsened relative to pretreatment state. Number of subjects with TEAEs included subjects with both non serious and serious TEAEs.
| participants | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| TEAEs | 46 | 40 | 39 | 52 |
| Serious TEAEs | 1 | 3 | 3 | 1 |
Collected over From the first dose of study drug administration up to 12 weeks after the last dose of the study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/63 (1.6%) | 33/63 (52.4%) |
| Atacicept 25 mg | — | 3/63 (4.8%) | 30/63 (47.6%) |
| Atacicept 75 mg | — | 3/63 (4.8%) | 34/63 (54%) |
| Atacicept 150 mg | — | 1/65 (1.5%) | 44/65 (67.7%) |
| Event | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/63 | 0/63 | 2/63 | 0/65 |
| Myocardial infarctionCardiac disorders | 1/63 | 0/63 | 0/63 | 0/65 |
| Hip fractureInjury, poisoning and procedural complications | 0/63 | 1/63 | 0/63 | 0/65 |
| Humerus fractureInjury, poisoning and procedural complications | 0/63 | 1/63 | 0/63 | 0/65 |
| Acute psychosisPsychiatric disorders | 0/63 | 1/63 | 0/63 | 0/65 |
| PleurisyRespiratory, thoracic and mediastinal disorders | 0/63 | 0/63 | 1/63 | 0/65 |
| Bronchopleural fistulaRespiratory, thoracic and mediastinal disorders | 0/63 | 0/63 | 1/63 | 0/65 |
| Lung abscessInfections and infestations | 0/63 | 0/63 | 1/63 | 0/65 |
| PyothoraxInfections and infestations | 0/63 | 0/63 | 1/63 | 0/65 |
| PneumoniaInfections and infestations | 0/63 | 0/63 | 1/63 | 0/65 |
| Event | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg |
|---|---|---|---|---|
| Injection site reactionGeneral disorders | 8/63 | 19/63 | 24/63 | 32/65 |
| NasopharyngitisInfections and infestations | 6/63 | 4/63 | 7/63 | 13/65 |
| HeadacheNervous system disorders | 11/63 | 8/63 | 3/63 | 6/65 |
| Upper respiratory tract infectionInfections and infestations | 3/63 | 1/63 | 4/63 | 8/65 |
| Urinary tract infectionInfections and infestations | 3/63 | 4/63 | 7/63 | 3/65 |
| InfluenzaInfections and infestations | 5/63 | 1/63 | 1/63 | 2/65 |
| BronchitisInfections and infestations | 1/63 | 2/63 | 1/63 | 5/65 |
| DiarrhoeaGastrointestinal disorders | 1/63 | 1/63 | 3/63 | 5/65 |
| Back painMusculoskeletal and connective tissue disorders | 4/63 | 0/63 | 3/63 | 3/65 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 4/63 | 3/63 | 1/63 | 1/65 |
Intent-to-treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg | Total |
|---|---|---|---|---|---|
| Mean | 37.7 ± 10.5 | 37.5 ± 8.5 | 38.0 ± 10.1 | 37.5 ± 10.5 | 37.7 ± 9.9 |
| Sex: Female, Male(Participants) | Placebo | Atacicept 25 mg | Atacicept 75 mg | Atacicept 150 mg | Total |
|---|---|---|---|---|---|
| Female | 45 | 34 | 44 | 46 | 169 |
| Male | 18 | 29 | 20 | 19 | 86 |
The record gives a start of Apr 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 6 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein